Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹114 Cr
Revenue (TTM)
₹276 Cr
Net Profit (TTM)
₹9 Cr
ROE
11.7 %
ROCE
13 %
P/E Ratio
12.1
P/B Ratio
0.5
Industry P/E
45.36
EV/EBITDA
6.8
Div. Yield
0 %
Debt to Equity
0.2
Book Value
₹43.2
EPS
₹1.7
Face value
2
Shares outstanding
55,207,500
CFO
₹-6.30 Cr
EBITDA
₹236.51 Cr
Net Profit
₹161.49 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Balaxi Pharmaceuticals
| -20.9 | 7.7 | -24.9 | -68.3 | -41.5 | -28.0 | -- |
|
BSE Healthcare
| -4.9 | -5.9 | -5.5 | 1.2 | 23.6 | 13.9 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Balaxi Pharmaceuticals
| -62.7 | -17.0 | -28.8 | 18.3 | -20.0 | 725.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Balaxi Pharmaceuticals
|
21.3 | 114.4 | 275.7 | 9.4 | 6.9 | 4 | 12.1 | 0.5 |
| 2,122.0 | 17,369.8 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.5 | 11.4 | |
| 655.4 | 12,799.2 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.4 | 2.3 | |
| 617.4 | 15,311.4 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.1 | 3.7 | |
| 834.1 | 13,050.7 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.2 | 2.0 | |
| 1,023.3 | 18,202.0 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.7 | 2.1 | |
| 1,430.9 | 16,332.4 | 1,419.3 | 20.1 | 8.4 | 0.5 | 812.5 | 2.8 | |
| 140.7 | 18,549.7 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.3 | |
| 390.7 | 15,714.6 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.6 | 3.3 | |
| 1,260.8 | 20,384.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 926.6 | 4.4 |
No Review & Analysis are available.
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various... therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. Balaxi Pharmaceuticals Limited was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited. Read more
Incorporated
1942
Chairman
--
Managing Director
Ashish Maheshwari
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Announcements
View AnnouncementsAlteration Of Capital and Fund Raising-XBRL
25-Jan-2024
The share price of Balaxi Pharmaceuticals Ltd is ₹21.25 (NSE) as of 02-Apr-2026 14:19 IST. Balaxi Pharmaceuticals Ltd has given a return of -41.49% in the last 3 years.
The P/E ratio of Balaxi Pharmaceuticals Ltd is 12.12 times as on 02-Apr-2026, a 73 discount to its peers’ median range of 45.36 times.
The P/B ratio of Balaxi Pharmaceuticals Ltd is 0.48 times as on 02-Apr-2026, a 85 discount to its peers’ median range of 3.12 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
12.75
|
1.52
|
|
2024
|
0.00
|
2.74
|
|
2023
|
2.09
|
3.13
|
|
2022
|
7.30
|
3.11
|
|
2021
|
14.09
|
8.07
|
The 52-week high and low of Balaxi Pharmaceuticals Ltd are Rs 73.70 and Rs 15.20 as of 02-Apr-2026.
Balaxi Pharmaceuticals Ltd has a market capitalisation of ₹ 114 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Balaxi Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹2.45
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.